Effects of Cangrelor on MIcRovAscular Disfunction During Elective Percutaneous CORonary Intervention (MIRACOR)
Coronary Artery Disease
About this trial
This is an interventional prevention trial for Coronary Artery Disease focused on measuring index of microcirculatory resistance, coronary flow reserve, Cangrelor
Eligibility Criteria
Inclusion Criteria: Adult patients; Signed Informed Consent; Chronic coronary syndromes; P2Y12-inhibitors naive patients; Elective PCI of a functionally significant (FFR ≤ 0.80) de-novo intermediate coronary artery stenoses in a major vessel; Exclusion Criteria: Underaged patients; Acute Conorary Syndromes; Already on treatment with P2Y12-inhibitors; Heart failure with severe reduction of the left ventricle ejection fraction (LVEF < 30%); Subtotal occlusion (diameter stenosis > 90%) of the target lesion;
Sites / Locations
- Division of Cardiology, University Hospital of Ferrara
- Division of Cardiology - Federico II University Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Cangrelor
Control
In the Experimental group, before performing PCI, all patients will be treated with Cangrelor (Kangrexal) with an i.v. loading bolus (30mg/Kg) followed by i.v. infusion (4mg/Kg/min) for 2 hours. At the end of the infusion, as per current clinical practice, a loading dose of Clopidogrel (600mg) will be administered. A manteinance daily dose of 75mg will be associated with oral ASA (100mg).
In the Control group, either before or after PCI a loading dose of Clopidogrel will be administered and a manteinance daily dose of 75mg will be associated with oral ASA (100mg). PCI procedure will be performed as per current cinical practice, according clinical guidelines and at operator discretion.